<http://schema.org/description>
"Isis sees its collaborative revenue soar, but higher R&amp;amp;D expenses and the lack of a one-time benefit causes its losses to balloon in the fourth quarter."^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.fool.com/investing/general/2014/02/28/isis-pharmaceuticals-q4-revenue-more-than-doubles.aspx>